Intensive smoking cessation programme reports limited success at 6 months

HIV Treat Bull - 2009 May-Jun;10(5/6): 09

Simon Collins, HIV i-Base

The scale of the problem of smoking often highlighted in discussions of the abacavir data with a comment such as ‘patients would reduce their risk more from stopping smoking rather than discontinuing abacavir not only is unhelpful for non- and ex-smokers but also of limited benefit for current smokers who have unsuccessfully tried to quit.

Karen Tashima presented results showing a limited 6 month success rate (~10%) in around 450 HIV-positive US smokers (average 18/day), randomised to more intense motivational interventions (ME; 4 long (30 minute) counselling sessions) compared to standard of care (SC; 2 brief 3 minute sessions), both with nicotine patches. While the study as a whole found no additional benefit to the ME programme, it had significant differences by race.

Only around 50% and 60% of patients attended the 2- and 4-month follow-up visits with an increase to 72% at 6-month possibly related to greater financial compensation at that time point. Overall, 6-month quit rates by intent-to-treat analysis were 9% (9% ME, 10% SC, p=0.76).

Higher quit rates were seen among Hispanic patients (19% overall, 14% ME, 24% SC) and lowest among African Americans (5% overall, 9% ME, 0% SC), with significant differences in the standard care arm (p=0.01). Failure to use nicotine replacement predicted smoking at 6 months (p<0.05).

Multivariate predictors of 6-month smoking abstinence among patch users included black race vs white (p=0.003), baseline self-ability or change in self-ability to refuse ciarettes (p<0.001), change in belief to quit (p=0.003).

Comment

Most commentators found these results depressing, including the presenter, although it was also pointed out that many people need to attend several programmes before they are successful.

Indeed, 68% of participants had previously used nicotine patches and 20% had previously managed to quit for over one year: highlighting the fragility of even these modest success rates.

Patients did not have to express an interest in trying to quit and the financial reimbursement may have encourged particpants with a low motivation. This intervention may have looked more impressive if patients had been selected more appropriately.

Ref: Tashima K et al. Positive paths: a motivational intervention for smoking cessation among HIV+ smokers. Conf Retroviruses Opportunistic Infect 2009 Feb 8-11;16: Oral abstract 148.

2009-05-10
IB2009-05-09

©2009. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.